依度沙班是凝血Xa因子直接抑制剂,于2015年1月8日由美国FDA批准上市,用于减少非瓣膜性房颤卒中和全身性栓塞的风险。依度沙班可每日1次口服给药,血药浓度平稳,患者依从性好,与其他药物的相互作用相对较少,使用方便,无须常规监测,大多数患者无需调整剂量。 Edo Saban, a direct inhibitor of coagulation factor Xa, was approved by the U.S. FDA on January 8, 2015 for use in reducing the risk of non-valvular atrial fibrillation and systemic embolism. Xindababan can be administered orally once daily on a daily basis with stable blood concentration, good patient compliance, less interaction with other drugs, ease of use and no routine monitoring, and most patients do not need to adjust the dosage.